Joseph Thome
Stock Analyst at TD Cowen
(2.49)
# 3,343
Out of 5,182 analysts
24
Total ratings
57.14%
Success rate
0.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLT MapLight Therapeutics | Initiates: Buy | n/a | $30.05 | - | 1 | Apr 7, 2026 | |
| UTHR United Therapeutics | Maintains: Buy | $575 → $660 | $588.38 | +12.17% | 4 | Mar 30, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $117 → $125 | $97.95 | +27.62% | 3 | Mar 27, 2026 | |
| PTCT PTC Therapeutics | Maintains: Hold | $50 → $63 | $72.43 | -13.02% | 3 | Nov 5, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $10 | $6.45 | +55.04% | 1 | Oct 31, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $89.90 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $14.80 | - | 1 | Nov 25, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $39.71 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $34.53 | -1.53% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $3.81 | - | 1 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.48 | - | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $59.70 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.78 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $188.99 | -31.21% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.95 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.99 | - | 1 | Nov 23, 2021 |
MapLight Therapeutics
Apr 7, 2026
Initiates: Buy
Price Target: n/a
Current: $30.05
Upside: -
United Therapeutics
Mar 30, 2026
Maintains: Buy
Price Target: $575 → $660
Current: $588.38
Upside: +12.17%
Mirum Pharmaceuticals
Mar 27, 2026
Maintains: Buy
Price Target: $117 → $125
Current: $97.95
Upside: +27.62%
PTC Therapeutics
Nov 5, 2025
Maintains: Hold
Price Target: $50 → $63
Current: $72.43
Upside: -13.02%
Ardelyx
Oct 31, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $6.45
Upside: +55.04%
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $89.90
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $14.80
Upside: -
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $39.71
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $34.53
Upside: -1.53%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $3.81
Upside: -
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.48
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $59.70
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.78
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $188.99
Upside: -31.21%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $14.95
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.99
Upside: -